Anixa Biosciences, Inc. ANIX 深 滬
等待開盤 12-25 09:30:00 美东时间
3.42
+0.120
+3.64%
華盛通- 最 高3.42
- 今 開3.31
- 成交量 7.47万股
- 最 低 3.2601
- 昨 收 3.30
- 總市值 1.13亿
- 52周最高 5.4566
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 2.07
- 委 比 59.84%
- 總股本 3291.69万
- 歷史最高 8.09
- 量 比 0.39
- 振 幅 4.85%
- 歷史最低 1.33
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
12-15 15:30
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.
12-12 20:23
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE, Calif., Nov. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. (...
11-12 22:00
Anixa Biosciences executes data transfer deal with Cleveland Clinic
Anixa Biosciences (ANIX) on Wednesday said that it has executed a data transfer agreement with the Cleveland Clinic as a key step in the process of transferring the breast cancer vaccine clinical tria...
11-05 21:58
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
Anixa Biosciences Completes The Final Patient Visit In Its Phase 1 Breast Cancer Vaccine Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of the final patient visit in its breast cancer
10-07 20:46
Anixa To Present Phase 1 Breast Cancer Vaccine Data At 2025 San Antonio Breast Cancer Symposium
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance
09-22 20:09
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 30 percent increase over losses of $(0.10) per share from
09-11 04:36
